Hologic is leveraging its recently acquired Claros analytics platform to integrate AI-driven imaging at the point of care, positioning its portable diagnostics to compete in a market projected to reach $70.92 billion by 2032. The company’s efforts align with the Centers for Medicare & Medicaid Services’ ACCESS Model, which begins in July 2026 and will reward providers for outcome-based imaging. Hologic reports that its mobile breast and general radiography units, enhanced with real-time lesion detection algorithms, have reduced repeat scans by 22% in pilot hospitals, cutting facility overhead by up to 18%.

In January 2026, Hologic rolled out Ultimate Defense, a nationwide public health initiative encouraging routine Pap and HPV co-testing. The campaign deploys digital outreach across 12 states with historically low screening rates, aiming to boost cervical cancer screening by 15% within 18 months. Hologic has partnered with 250 community clinics to distribute free HPV self-collection kits and educational materials, targeting 1 million women aged 21–65 who have not been screened in over three years.

Hologic plans to release its first-quarter fiscal 2026 results on January 29 after market close, but will not host a conference call or provide forward guidance due to its pending acquisition by Blackstone and TPG. The company’s management cited regulatory review timelines and integration planning as reasons for withholding guidance. Investors will watch reported revenue trends in diagnostics and breast health divisions, which collectively generated approximately 68% of total fiscal 2025 sales.